Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Optimizing transplantation outcomes in patients with AML

Eleni Gavriilaki • 11 Jun 2022
EHA 2022
Acute Myeloid Leukemia Leukemia

Eleni Gavriilaki, MD, PhD, G Papanicolaou Hospital, Thessaloniki, Greece, discusses recent advances in strategies to optimize the outcomes of patients with acute myeloid leukemia (AML) who receive an allogeneic transplant, including reduced-intensity conditioning (RIC) and more personalized treatment approaches. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Eleni Gavriilaki

0:58
Agents under investigation for the treatment of TA-TMA
Eleni Gavriilaki • 16 Feb 2024
1:03
Cognitive impairment in patients receiving CAR T-cell therapy
Eleni Gavriilaki • 16 Feb 2024
0:52
Long-term complications in patients with hematological malignancies post-SCT
Eleni Gavriilaki • 11 Dec 2023
1:19
The potential of caplacizumab in the treatment of aTTP
Eleni Gavriilaki • 11 Dec 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals